7 results about "Isopropylmalic acid" patented technology

The present disclosure relates to the field of bioengineered yeast strains as therapeutic platforms. In particular, engineered strains of yeast brassicae comprising a nucleic acid encoding a modified 3-isopropylmalate dehydrogenase (Leu2) and a therapeutic protein, and methods for treating or preventing a disease or condition in a subject in need thereof.

The invention discloses yarrowia lipolytica engineering bacteria for producing esterified astaxanthin as well as a construction method and application of the yarrowia lipolytica engineering bacteria. According to the invention, acyltransferase ScDGAT2-1 from fission vibrio is integrated in a genome of a yarrowia lipolytica engineering strain DN20, diacylglycerol acyltransferase DGA1 and phosphatidic acid phosphatase PAH1 are knocked out, and the corn oil lipoprotein Oleosin and the acyltransferase ScDGAT2-1 from fission vibrio are subjected to fusion expression, so that the yarrowia lipolytica engineering strain DN20 is obtained. According to the present invention, the Yarrowia lipolytica engineering bacterium capable of producing esterified astaxanthin at a high yield is constructed by using SBT06-005 as a raw material and integrating beta-carotene hydroxylase CrtZ, endogenous truncated 3-hydroxy3-methylglutaryl coenzyme A reductase tHMG1, phytoene synthase CarRP and beta-isopropyl malate dehydrogenase LEU2, and the SBT06-005 can produce 166.6 mg / L esterified astaxanthin and 1097.0 mg / L total astaxanthin in a 5L fermentation tank.

The application discloses tobacco isopropyl malate dehydrase NtIPDS, a coding gene, an RNAi interference carrier and application. The application successfully clones a coding gene of isopropyl malate dehydrase in tobacco, and the nucleotide sequence is as follows: (1) the nucleotide sequence shown in SEQ ID NO. 1; (2) the nucleotide sequence shown in SEQ ID NO. 1 is substituted and / or deleted and / or added with one or more nucleotides and the nucleotide sequence of the same functional protein. Based on the existing tobacco genetic engineering progress and related plant phenotype observation and identification, the NtIPDS gene is deeply researched, and it is found that the NtIPDS gene is related to tobacco chloroplast development and acyl sugar metabolism. After the gene is silenced, the chlorosis plant growth is slow, the chloroplast development is found to be abnormal through transmission electron microscope observation, and meanwhile, it is found that the acyl sugar content of the silenced plant is significantly increased through metabolic detection analysis.

The present disclosure relates to an isopropylmalate synthase variant and a method of producing L-leucine using the same.

The present application relates to: a novel mutant polypeptide having isopropylmalate synthase activity; and a method for producing L-leucine by using same. L-leucine can be produced at high yield by using the mutant polypeptide according to an embodiment.

This disclosure relates to the field of bioengineered yeast strains as therapeutic platforms. In particular, to genetically modified strains of Saccharomyces bouloidii yeast containing modified 3-isopropylmalate dehydrogenase (Leu2) and nucleic acids encoding therapeutic proteins, as well as methods for treating or preventing diseases or conditions in subjects requiring such treatment.

The invention belongs to the technical field of biology, and particularly relates to an isopropyl malic acid synthase mutant and application thereof. The isopropyl malic acid synthase mutant is obtained based on random mutation of an error-prone PCR technology, and the enzyme activity of the isopropyl malic acid synthase mutant is greatly improved; the L-leucine yield of a recombinant strain constructed by the mutant is remarkably improved, and the mutant has a relatively high practical value.